AION Labs launches new startup using AI to discover molecular glue therapies

AION Labs, an AI-enabled drug discovery partnership, has launched a new startup called TenAces. TenAces will use AI to discover molecular glue therapies to enhance targeted protein degradation, potentially treating cancer and neurodegenerative diseases. The company will integrate biology into its machine learning algorithms and work with pharma partners to develop and commercialize solutions. AION Labs is supported by the Israeli government and includes pharma giants AstraZeneca, Merck, Pfizer, and Teva, as well as venture capital and research partners. AION has also announced partnerships with other early-stage venture capital firms and previously launched startups focused on computational drug assessment and antibody discovery.

Source link

error: Content is protected !!